RecruitingPhase 3NCT05586802

Sex Steroids Balance for Metabolic and Reproductive Health in Klinefelter Syndrome

Dissecting the Importance of Sex Steroids Balance for Metabolic and Reproductive Health in Men With Klinefelter Syndrome: a Randomized Controlled Study


Sponsor

Georgios Papadakis

Enrollment

150 participants

Start Date

Mar 21, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

The study seeks primarily to determine whether modulation of systemic and testicular sex steroids balance by aromatase inhibitors will positively affect the metabolic health and spermatogenesis of men with Klinefelter syndrome (KFS) as compared to the current state of the art for each issue. Secondary objectives of this study are (i) to unravel the heterogeneity of the reproductive and metabolic phenotype of men with KFS by performing a multi-omic analysis in a large cohort at baseline; (ii) to evaluate the efficacy of semaglutide-induced weight loss to achieve metabolic and reproductive benefit in men with Klinefelter syndrome as compared to standard testosterone replacement; (ii) to assess whether addition of hCG to aromatase inhibitors further increases intratesticular testosterone and promotes spermatogenesis in men with KFS.


Eligibility

Sex: MALEMin Age: 16 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating whether adjusting the balance of sex hormones using aromatase inhibitors (and sometimes hCG) can improve fertility and metabolic health in men with Klinefelter syndrome (KS), a genetic condition affecting males who have an extra X chromosome. It also examines whether the weight-loss medication semaglutide can improve metabolic outcomes in men with KS who are overweight. You may be eligible if you have a confirmed diagnosis of Klinefelter syndrome and are either aged 16 to 40 with fertility goals or 18 to 65 with metabolic concerns and no interest in fertility treatment. Participation involves blood tests, medical assessments, and taking assigned medications over the course of the study. This summary was prepared using AI to help patients understand this research.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAnastrozole

This will be an experimental treatment for 26 weeks in Group 1 Arm A and Arm B as well for Group 2 Arm D

DRUGSemaglutide

This will be an experimental treatment for 26 weeks in Group 2 Arm E

DRUGhuman chorionic gonadotropin

This will be an experimental treatment for 26 weeks in addition to anastrozole in Group 1 - Arm B

DRUGTestosterone gel

This will be an active comparator for 26 weeks in Group 2 - Arm C


Locations(1)

Service of Endocrinology, Diabetes & Metabolism

Lausanne, Switzerland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05586802


Related Trials